12 assets in DNA Repair Disease

Therapeutic assets addressing DNA Repair Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab DNA Repair Disease	National Cancer Institute (NCI)	P3	B (60)
Fluorouracilum DNA Repair Disease	National Cancer Institute (NCI)	P3	B (60)
Oxaliplatin DNA Repair Disease	National Cancer Institute (NCI)	P3	B (58)
Abiraterone DNA Repair Disease	Northwestern University	P2	CCC (53)
Docetaxel DNA Repair Disease	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	CCC (53)
Durvalumab DNA Repair Disease	UNICANCER	P2	CCC (53)
Fulvestrant DNA Repair Disease	UNICANCER	P2	CCC (53)
Olaparib DNA Repair Disease	UNICANCER	P2	CCC (53)
Prednisolone DNA Repair Disease	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	CCC (53)
Prednisone DNA Repair Disease	Northwestern University	P2	CCC (53)
Cyclosporin A DNA Repair Disease	Virginia G. Kaklamani	Early P1	C (39)
dsb2455 DNA Repair Disease	Duke Street Bio Ltd	P1	NR ()